Immuno-Oncology Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1065045
  • May 2021
  • Pharmaceuticals
  • 127 Pages
The Immuno-Oncology Drugs Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Amgen, Inc., Astrazeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli lilly and Company, Sanofi, F. Hoffmann-La Roche, Novartis AG, Abbvie, Inc., Pfizer Inc.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Immuno-Oncology Drugs market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Immuno-Oncology Drugs market is expected to attain Pre COVID-19 levels by mid-2022.

Immuno-Oncology Drugs Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Immuno-Oncology Drugs market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Immuno-Oncology Drugs Market Competitive and Premeditated Analysis
In the Immuno-Oncology Drugs report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Immuno-Oncology Drugs research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Immuno-Oncology Drugs Market:
The Immuno-Oncology Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Amgen, Inc., Astrazeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli lilly and Company, Sanofi, F. Hoffmann-La Roche, Novartis AG, Abbvie, Inc., Pfizer Inc.

The Immuno-Oncology Drugs market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Immuno-Oncology Drugs Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Immuno-Oncology Drugs market:
by Drug Type
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cytokine Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Therapeutic Application
Melanoma
Lung Cancer
Blood Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Others
End User
Hospitals
Clinics
Ambulatory Surgical Centers

Regional Analysis of the Immuno-Oncology Drugs market:
The Immuno-Oncology Drugs market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Immuno-Oncology Drugs report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Immuno-Oncology Drugs market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Immuno-Oncology Drugs market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Immuno-Oncology Drugs market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Immuno-Oncology Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Immuno-Oncology Drugs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Immuno-Oncology Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Immuno-Oncology Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Immuno-Oncology Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Amgen, Inc.
  • Astrazeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli lilly and Company
  • Sanofi
  • F. Hoffmann-La Roche
  • Novartis AG
  • Abbvie, Inc.
  • Pfizer Inc.
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cytokine Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Immuno-Oncology Drugs Market Snapshot
          2.1.1. Global Immuno-Oncology Drugs Market By Drug Type,2019
               2.1.1.1.Immune Checkpoint Inhibitors
               2.1.1.2.Monoclonal Antibodies
               2.1.1.3.Cytokine Based Immunotherapy
               2.1.1.4.Cancer Vaccines
               2.1.1.5.CAR-T Cell Therapy
          2.1.2. Global Immuno-Oncology Drugs Market By End User,2019
               2.1.2.1.Hospitals
               2.1.2.2.Clinics
               2.1.2.3.Ambulatory Surgical Centers
          2.1.3. Global Immuno-Oncology Drugs Market By End-use,2019
          2.1.4. Global Immuno-Oncology Drugs Market By Geography,2019

3. Global Immuno-Oncology Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Drug Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Drug Type, 2020
     4.2. Global Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028

5. Global Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028

6. Global Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Immuno-Oncology Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Immuno-Oncology Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Immuno-Oncology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028
          7.2.3. North America Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Immuno-Oncology Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Immuno-Oncology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028
          7.3.3. Europe Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Immuno-Oncology Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Immuno-Oncology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028
          7.4.3. Asia Pacific Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Immuno-Oncology Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Immuno-Oncology Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028
          7.5.3. Latin America Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Immuno-Oncology Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Immuno-Oncology Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Immuno-Oncology Drugs Market Size (US$), By Drug Type, 2018 – 2028
          7.6.3. MEA Immuno-Oncology Drugs Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Immuno-Oncology Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Immuno-Oncology Drugs Providers
        8.4.1 Amgen, Inc.
                8.4.1.1 Business Description
                8.4.1.2 Amgen, Inc. Geographic Operations
                8.4.1.3 Amgen, Inc. Financial Information
                8.4.1.4 Amgen, Inc. Product Positions/Portfolio
                8.4.1.5 Amgen, Inc. Key Developments
        8.4.2 Astrazeneca Plc
                8.4.2.1 Business Description
                8.4.2.2 Astrazeneca Plc Geographic Operations
                8.4.2.3 Astrazeneca Plc Financial Information
                8.4.2.4 Astrazeneca Plc Product Positions/Portfolio
                8.4.2.5 Astrazeneca Plc Key Developments
        8.4.3 Bristol-Myers Squibb
                8.4.3.1 Business Description
                8.4.3.2 Bristol-Myers Squibb Geographic Operations
                8.4.3.3 Bristol-Myers Squibb Financial Information
                8.4.3.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.4.3.5 Bristol-Myers Squibb Key Developments
        8.4.4 Celgene Corporation
                8.4.4.1 Business Description
                8.4.4.2 Celgene Corporation Geographic Operations
                8.4.4.3 Celgene Corporation Financial Information
                8.4.4.4 Celgene Corporation Product Positions/Portfolio
                8.4.4.5 Celgene Corporation Key Developments
        8.4.5 Eli lilly and Company
                8.4.5.1 Business Description
                8.4.5.2 Eli lilly and Company Geographic Operations
                8.4.5.3 Eli lilly and Company Financial Information
                8.4.5.4 Eli lilly and Company Product Positions/Portfolio
                8.4.5.5 Eli lilly and Company Key Developments
        8.4.6 Sanofi
                8.4.6.1 Business Description
                8.4.6.2 Sanofi Geographic Operations
                8.4.6.3 Sanofi Financial Information
                8.4.6.4 Sanofi Product Positions/Portfolio
                8.4.6.5 Sanofi Key Developments
        8.4.7 F. Hoffmann-La Roche
                8.4.7.1 Business Description
                8.4.7.2 F. Hoffmann-La Roche Geographic Operations
                8.4.7.3 F. Hoffmann-La Roche Financial Information
                8.4.7.4 F. Hoffmann-La Roche Product Positions/Portfolio
                8.4.7.5 F. Hoffmann-La Roche Key Developments
        8.4.8 Novartis AG
                8.4.8.1 Business Description
                8.4.8.2 Novartis AG Geographic Operations
                8.4.8.3 Novartis AG Financial Information
                8.4.8.4 Novartis AG Product Positions/Portfolio
                8.4.8.5 Novartis AG Key Developments
        8.4.9 Abbvie, Inc.
                8.4.9.1 Business Description
                8.4.9.2 Abbvie, Inc. Geographic Operations
                8.4.9.3 Abbvie, Inc. Financial Information
                8.4.9.4 Abbvie, Inc. Product Positions/Portfolio
                8.4.9.5 Abbvie, Inc. Key Developments
        8.4.10 Pfizer Inc.
                8.4.10.1 Business Description
                8.4.10.2 Pfizer Inc. Geographic Operations
                8.4.10.3 Pfizer Inc. Financial Information
                8.4.10.4 Pfizer Inc. Product Positions/Portfolio
                8.4.10.5 Pfizer Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Immuno-Oncology Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Immuno-Oncology Drugs Market Revenue, By Drug Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Immuno-Oncology Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Immuno-Oncology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Immuno-Oncology Drugs Market Revenue, By Drug Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Immuno-Oncology Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Immuno-Oncology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Immuno-Oncology Drugs Market Revenue, By Drug Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Immuno-Oncology Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Immuno-Oncology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Immuno-Oncology Drugs Market Revenue, By Drug Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Immuno-Oncology Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Immuno-Oncology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Immuno-Oncology Drugs Market Revenue, By Drug Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Immuno-Oncology Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Immuno-Oncology Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Immuno-Oncology Drugs: Market Segmentation 
FIG. 2 Global Immuno-Oncology Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Immuno-Oncology Drugs Market, By Drug Type, 2019 (US$ Mn) 
FIG. 5 Global Immuno-Oncology Drugs Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Immuno-Oncology Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Immuno-Oncology Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Immuno-Oncology Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Immuno-Oncology Drugs Providers, 2019
FIG. 11 Global Immuno-Oncology Drugs Market Revenue Contribution, By Drug Type, 2019 & 2028 (Value %) 
FIG. 12 Global Immuno-Oncology Drugs Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Immuno-Oncology Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Immuno-Oncology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Immuno-Oncology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Immuno-Oncology Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Immuno-Oncology Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Immuno-Oncology Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Immuno-Oncology Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Immuno-Oncology Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Immuno-Oncology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Immuno-Oncology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Immuno-Oncology Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Immuno-Oncology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Immuno-Oncology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Immuno-Oncology Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Immuno-Oncology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Immuno-Oncology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Immuno-Oncology Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Immuno-Oncology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Immuno-Oncology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Immuno-Oncology Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Immuno-Oncology Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Immuno-Oncology Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Immuno-Oncology Drugs Market Value, By Country, 2018 – 2028
TABLE  Amgen, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Astrazeneca Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celgene Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbvie, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Immuno-Oncology Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Immuno-Oncology Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Immuno-Oncology Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Immuno-Oncology Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Immuno-Oncology Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Immuno-Oncology Drugs Providers, 2016
FIG.  Global Immuno-Oncology Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Monoclonal Antibodies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Cytokine Based Immunotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Cancer Vaccines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global CAR-T Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Immuno-Oncology Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ambulatory Surgical Centers Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Immuno-Oncology Drugs Market Value, 2018 – 2028, (US$ Mn)